 |
BioWorld-Insight-2003-06-16
Stock Winners and Losers For The Week
Neurocrine, Sepracor Race To Unseat Ambien For Insomnia
With a Phase III program in full swing for its insomnia drug Indiplon (formerly NBI-34060), Neurocrine Biosciences Inc. unveiled full Phase II data for the first time during the meeting of the Associated Professional Sleep Societies earlier this month in Chicago. (BioWorld Financial Watch)
Non-U.S. Clinical Trials, Regulatory Submissions, Recommendations And Approvals: May 2003
No Abstract